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a b s t r a c t
Prolonged exposure to hyperoxia results in acute lung injury (ALI), accompanied by a signiﬁcant eleva-
tion in the levels of proinﬂammatory cytokines and leukocyte inﬁltration in the lungs. However, the
mechanisms underlying hyperoxia-induced proinﬂammatory ALI remain to be elucidated. In this study,
we investigated the role of the proinﬂammatory cytokine high mobility group box protein 1 (HMGB1) in
hyperoxic inﬂammatory lung injury, using an adult mouse model. The exposure of C57BL/6 mice to
Z99% O2 (hyperoxia) signiﬁcantly increased the accumulation of HMGB1 in the bronchoalveolar lavage
ﬂuids (BALF) prior to the onset of severe inﬂammatory lung injury. In the airways of hyperoxic mice,
HMGB1 was hyperacetylated and existed in various redox forms. Intratracheal administration of
recombinant HMGB1 (rHMGB1) caused a signiﬁcant increase in leukocyte inﬁltration into the lungs
compared to animal treated with a non-speciﬁc peptide. Neutralizing anti-HMGB1 antibodies, admini-
strated before hyperoxia signiﬁcantly attenuated pulmonary edema and inﬂammatory responses, as
indicated by decreased total protein content, wet/dry weight ratio, and numbers of leukocytes in the
airways. This protection was also observed when HMGB1 inhibitors were administered after the onset of
the hyperoxic exposure. The aliphatic antioxidant, ethyl pyruvate (EP), inhibited HMGB1 secretion from
hyperoxic macrophages and attenuated hyperoxic lung injury. Overall, our data suggest that HMGB1
plays a critical role in mediating hyperoxic ALI through the recruitment of leukocytes into the lungs.
If these results can be translated to humans, they suggest that HMGB1 inhibitors provide treatment
regimens for oxidative inﬂammatory lung injury in patients receiving hyperoxia through mechanical
ventilation.
& 2014 The Authors. Published by Elsevier B.V. All rights reserved.
Introduction
Oxygen therapy with supraphysiological concentrations of oxy-
gen (hyperoxia) is routinely administered during mechanical venti-
lation (MV) for the management of severe respiratory distress, such
as acute respiratory distress syndrome [12,14,51]. However, oxygen
therapy can also cause oxygen toxicity, inducing acute lung injury
(ALI) [21,38]. Hyperoxia-induced ALI is characterized by excessive
proinﬂammatory responses, endothelial and epithelial cell damage,
and alveolar edema [9,13,20,35]. Although hyperoxia-induced ALI is
mediated by excessive amounts of reactive oxygen species (ROS),
the more severe ALI is associated with the inﬂux of leukocytes
including polymorphonuclear neutrophils (PMNs) into the lungs
[6,47]. Both chemokines and pro-inﬂammatory cytokines are critical
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in mediating neutrophil recruitment into the lungs [5,34]. For
example, chemokines, such as MIP-1, CXCL1, CXCL2 and IL-8, are
involved in the regulation of neutrophil recruitment [18,34].
Although pro-inﬂammatory cytokines, including TNF-α and IL-1β
have been implicated in mediating neutrophil inﬂux into hyperoxic
lungs [17,18], molecular mechanisms underlying PMNs recruitment
under hyperoxic conditions remain to be elucidated. Clinically, there
are no effective treatments that reduce the inﬂammatory lung
injury of patients on mechanical ventilation.
High mobility group box 1 (HMGB1), originally identiﬁed as a
nuclear DNA-binding protein [26], is critical for transcription regula-
tion and gene expression [39,45]. Numerous studies have reported
that extracellular HMGB1, as a pro-inﬂammatory cytokine, can trigger
an overwhelming inﬂammatory response that promotes the progres-
sion of sepsis and ALI [1,24,29,43,49]. In addition, the intratracheal
administration of recombinant HMGB1 (rHMGB1) to mice causes
pulmonary pro-inﬂammatory responses, including neutrophil accu-
mulation and release of cytokines such as IL-1β, TNF-α, MIP-2 and
macrophage migration inhibitory factor [1,24]. Clinically, elevated
levels of HMGB1, in both plasma and lung epithelial lining ﬂuids,
have been observed in patients with ALI [43,57]. Moreover, reduction
of levels of extracellular HMGB1 results in reduced inﬂammatory
responses and protection against organ failure in sepsis and endotox-
emia [49,50,54]. Thus, there appears to be a link between extracellular
HMGB1 and the pathogenesis of ALI, although little is known about
the role of HMGB1 in oxidative stress-induced hyperoxic ALI.
High levels of airway HMGB1 were found in bronchoalveolar
lavage ﬂuids (BALF) of patients receiving MV and in animals
subjected to high tidal volume ventilation [47]. Based on published
studies, we hypothesize that extracellular HMGB1 is an important
mediator of neutrophil inﬁltration in hyperoxic lungs and con-
tributes to the development of hyperoxia-induced inﬂammatory
ALI. In this report, we show that airway HMGB1 mediates the
recruitment of neutrophils to the lungs upon prolonged exposure
to hyperoxia, causing pronounced inﬂammatory ALI. The inhibi-
tion of HMGB1 by neutralizing anti-HMGB1 antibodies and the
small molecule ethyl pyruvate (EP) signiﬁcantly reduces HMGB1-
induced neutrophil inﬁltration and attenuate ALI.
Materials and methods
Mice and treatments
Mice were housed and used in the experimental protocols in
speciﬁc pathogen-free conditions in accordance with the Feinstein
Institute for Medical Research and St. John's University's Institu-
tional Animal Care and Use Committee Guidelines. Male C57BL/6
mice (6–8 weeks old) were purchased from Jackson Laboratories
(Bar Harbor, Maine). Mice were exposed to Z99% O2 at atmo-
spheric pressure in a Plexiglass chamber as described previously
[28,31] and the level of O2 in the chamber was constantly
monitored using an oxygen analyzer (BioSpherix Ltd., Redﬁeld,
NY). The environmental temperature was maintained at 2271 1C
and relative humidity was 62710%. Exposures were continuous
for the time indicated except for 5 min twice daily after 24 h
exposure, when the chamber was opened to allow intraperitoneal
administrations.
To inhibit HMGB1, mice received either 360 μg/mouse of anti-
HMGB1 IgGs or 40 mg/kg body weight EP (Sigma Aldrich, St. Louis,
MO) by intraperitoneal injection, while the mice in the control
groups received nonimmune IgGs or saline solution, respectively.
Each group contained between 5 and 13 animals, and experiments
were performed independently at least twice. After mice were
euthanized by sodium pentobarbital (10 mg/kg intraperitoneal
body weight), one lobe of the lungs was excised, weighed, and
dried in an oven at 80 1C and weighed again; the other lobes of
lung tissue were snap frozen in liquid nitrogen for molecular
analyses as previously described [28]. To obtain BALF, the mice
were anesthetized as described previously. A 1–2 cm incision was
made on the front part of animals' neck as described previously
[24]. The trachea was directly visualized, and a 20-gauge1-in.
intravenous catheter was inserted caudally into the lumen of
exposed trachea and secured in place. The lungs were then gently
lavaged with two aliquots of saline (total 2.5 ml), which were
pooled and the total cell count and cell differential were assessed.
Wet/dry weight ratios
All mice used for lung wet/dry weight ratios were of identical
ages. Lungs were excised, rinsed brieﬂy in PBS, blotted, and then
weighed to obtain the “wet” weight. Lungs were then dried in an
oven at 80 1C for 7 days to obtain the “dry” weight.
Instillation of rHMGB1
The instillation of rHMGB1 was performed as described pre-
viously [24]. Mice were anesthetized by intraperitoneal injection of
ketamine (75 mg/kg)/medetomidine (1.0 mg/kg). An incision (2–
3 mm) was made to visualize the trachea. A 25-gauge needle was
used to puncture the trachea, and the rHMGB1 was instilled using a
50-ml Hamilton syringe. Glutathion-S-transferase (GST) tag (Amer-
sham Pharmacia Biotech, Piscataway, NJ) was similarly instilled in
control animals.
Histopathology
Histopathological evaluation was performed on parafﬁn-
embedded tissues as described previously [30]. Before removal from
the animal, the lungs were rinsed with PBS and then instilled with
0.75 ml of buffered formalin through a 20-gauge angiocatheter
placed in the trachea. The lungs were then immersed in buffered
formalin overnight and processed for conventional parafﬁn histology.
The sections were stained with hematoxylin and eosin and examined
by light microscopy.
Cell culture
Murine macrophage-like RAW 264.7 cells (American Type Culture
Collection, Boulevard Manassas, VA) were cultured in RPMI medium
1640 (Gibco BRL, Grand Island, NY) supplemented with 10% FBS
(Gemini Biological Produces, Catabasas, CA), 1% penicillin and strepto-
mycin (Life Technologies, Carlsbad, CA). Cells were maintained at 37 1C
in 21% O2/5% CO2 (normoxia) and allowed to grow to 80–90%
conﬂuence. Hyperoxic exposure was performed in sealed humidiﬁed
modular incubator chambers (Billups-Rothenberg Inc. Del Mar, CA)
containing 95% O2/5% CO2 (hyperoxia) at 37 1C and medium was
changed daily as previously described [31].
Western blot analysis
All procedures were performed as described previously [16].
Samples were ultra-ﬁltered with Centricon 100 (Millpore, Billerica,
MA). Protein from each samples were loaded on a 10% SDS-
polyacrylamide gel transferred to a nitrocellulose membrane. After
being blocked with 5% non-fat milk the membrane was incubated
overnight at 4 1C with a speciﬁc polyclonal rabbit primary anti-
body to HMGB1 (kindly provided by Dr. Wang, from The Feinstein
Institute for Medical Research, North Shore-LIJ Health System,
Manhasset, NY) followed by incubation with an anti-rabbit horse-
radish peroxidase-coupled secondary antibody (Bio-Rad, Hercules,
CA). After three washings, bands were detected using enhanced
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chemiluminescence plus Western blotting detection reagents
(Amersham Pharmacia Biotech, Piscataway, NJ).
Immunohistochemical analysis
The localization of intracellular HMGB1 was assessed by immu-
nohistochemical analysis as previously described [15]. RAW 264.7
cells were seeded onto chamber slides (BD Bioscience, Bedford, MA),
ﬁxed with phosphate-buffered formaldehyde (2%, pH 7.4, 15 min)
after hyperoxic exposure. Immunohistochemical analysis of the
expression of HMGB1 was performed on parafﬁn-embedded tissues
as described above. The sections were de-waxed in xylene and
rehydrated with ethanol arranged in a graded concentration. Then
both ﬁxed RAW cells and de-waxed tissues were permeabilized with
0.2% Triton X-100 (Sigma Aldrich, St. Louis, MO). After blocking the
slides with 10% normal goat serum (Chemicon, Temecula, CA) cells
were incubated with anti-HMGB1 antibodies for 1 h. Raw cells and
lung tissues were incubated with anti-rabbit IgG (Molecular probes,
Eugene, OR) and horseradish peroxidase conjugated secondary anti-
body, respectively, for 1 h. Normal non-speciﬁc serum was used as a
negative control. Peroxidase-linked secondary antibody and diamino-
benzidine (DAB) (Vectastain ABC elite kit; Vector Laboratories, Bur-
lingame, CA) were used to detect speciﬁc binding. The sections were
counterstained with hematoxylin as described previously [42] and
examined using light microscopy (Olympus America Inc., Center
Valley, PA). RAW cells were counterstained with 4,6-diamidine-2-
phenylindole dihydrochloride (DAPI) (Roche Molecular Biochemicals,
Indianapolis, IN) to visualize the nuclei using immunoﬂuorescence
microscopy (Nikon, Melville, NY).
Analysis of HMGB1 by liquid chromatography tandem mass
spectrometry (LC–MS/MS)
All chemicals and solvents were of the highest available grade
(Sigma-Aldrich, Poole, UK). Samples were pre-cleared with 50 ml
protein G-Sepharose beads for 1 h at 4 1C. Supernatant HMGB1
was immunoprecipitated with 5 mg rabbit anti-HMGB1 (Abcam,
Cambridge, UK) for 16 h at 4 1C as previously described [3]. Free
thiol groups within HMGB1 were alkylated for 90 min with 10 mM
iodoacetamide at 4 1C. Cysteine residues in disulﬁde bonds were
then reduced with 30 mM dithiothreitol (DTT) at 4 1C for 1 h
followed by alkylation of newly exposed thiol groups with 90 mM
NEM at 4 1C for 10 min. Samples were subjected to GluC (New
England Biolabs, Herts, UK) digestion according to manufacturer's
instructions and de-salted using ZipTip C18 pipette tips (Millipore,
Consett, UK). The characterization of acetylated lysine residues
within HMGB1 was determined as described previously [2,32]
using an AB Sciex TripleTOF 5600 (Sciex Inc.).
Statistical analysis
All experiments were performed independently twice. The data
are presented as mean7standard error, and analyzed for statis-
tical signiﬁcance using the one-way analysis of variance (ANOVA).
A P value of r0.05 was considered signiﬁcant.
Result
Hyperoxia-induced inﬂammatory acute lung injury is associated with
elevated levels of airway HMGB1
To determine whether extracellular HMGB1 may contribute to
hyperoxia-induced ALI, markers of inﬂammatory ALI and levels of
airway HMGB1 were assessed by Western blot analysis in the BALF of
C57BL/6 mice that were exposed to hyperoxia (Z99% O2) for up to
4 days. As shown in Fig. 1A, airway HMGB1 became detectable in the
BALF after 2 days of hyperoxic exposure and the signal became more
pronounced after 3 and 4 days of exposure. Prolonged hyperoxic
exposure (4 days) signiﬁcantly increased markers of inﬂammatory
ALI, including the levels of total protein content (Fig. 1B) and total
PMNs count in BALF (Fig. 1C), as well as wet/dry weight ratio (Fig. 2B).
The levels of total protein content in lung BALF were
0.4270.003103 mg/ml at day 1, 0.5270.003103 mg/ml at day 2,
1.9170.03103 mg/ml at day 3, and 4.6270.06103 mg/ml at day 4,
compared to 0.4570.003103 mg/ml in animals remained at room
air (RA, 21% O2) (Fig. 1B). There was a signiﬁcant elevation of PMNs in
the airways (0.2470.02104/ml BALF at day 3 and 2.4770.6104/
ml BALF at day 4) (Fig. 1C). These data indicate a relationship between
Exposure to Hyperoxia (d) 
0                  1                2             3              4
Exposure to Hyperoxia (d) Exposure to Hyperoxia (d) 
0             1             2             3            4  0                 1              2                 3              4
HMGB1 
Fig. 1. Hyperoxia-induced lung injury is associated with increased accumulation of HMGB1 in the airways. C57BL/6 mice were exposed to Z99% O2 for indicated days
(d) or remained at RA (Exposure to hyperoxia ¼ 0 d). Levels of airway HMGB1 were analyzed by western blot analysis in mouse bronchoalveolar lavage ﬂuids (BALF). Blots
shown are representative of three independent experiments with similar results (A). Total protein content (B) and neutrophil (PMNs) inﬁltration (C) in the airway were
analyzed as markers of inﬂammatory ALI. Data represent means7SE from two independent experiments, n¼9 mice per group. n, Statistically signiﬁcant vs. the values of the
control group that remained at RA (Exposure to hyperoxia ¼ 0 d), Po0.05.
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elevated levels of airway HMGB1 and signiﬁcant inﬂammatory lung
injury in mice subjected to prolonged hyperoxic exposure.
Pretreatment with anti-HMGB1 antibodies protects against
hyperoxia-induced inﬂammatory acute lung injury
To establish a causal relationship between elevated levels of airway
HMGB1 and hyperoxia-induced inﬂammatory ALI, neutralizing poly-
clonal anti-HMGB1 IgGs [49] were administered to mice prior to
exposure to hyperoxia. Mice pretreated with anti-HMGB1 IgGs had
signiﬁcantly decreased hyperoxia-induced protein leakage into the
airways compared to mice that received control IgGs (2.470.25
103 mg/ml vs. 4.6270.64103 mg/ml; Po0.01) (Fig. 2A). In addition,
mice receiving anti-HMGB1 IgGs had signiﬁcantly less lung edema, as
measured by thewet/dry weight ratio, compared to mice that received
control IgGs (Fig. 2B, 1.170.02 vs. 1.3670.04; Po0.005). In contrast,
there was no statistically signiﬁcant difference in these inﬂammatory
ALI parameters between mice that received control IgGs and those
exposed to hyperoxia alone (Fig. 2A and B). These data indicate that
inhibiting airway HMGB1 attenuated lung injury, suggesting that
HMGB1 plays a key role in mediating hyperoxic lung injury.
Hyperoxia induces hyperacetylation and translocation of nuclear
HMGB1 to the cytoplasm
HMGB1, which plays an important role in the regulation of
gene transcription in the nuclei [10], also contributes to the
pathogenesis of various inﬂammatory diseases upon release into
the extracellular milieu [7,19]. To determine whether hyperoxia-
induced HMGB1 release into the airways is a result of the
translocation of HMGB1 from the nuclei to the cytoplasm, an
indicator of active release from cells not undergoing cell death,
immunohistochemical analysis was performed in lung tissue
sections of mice exposed to hyperoxia for 4 days. In mice that
remained at RA (Fig. 3A, RA), HMGB1 was found predominantly in
the nuclei of most lung cells. In contrast, HMGB1 was localized
mainly in the cytoplasm of many lung cells in mice exposed to
hyperoxia (Fig. 3A, O2). Thus, prolonged hyperoxic exposure
resulted in HMGB1 translocation from the nuclei to the cytoplasm
of lung cells. To conﬁrm our in vivo ﬁndings, HMGB1 localization
was characterized in murine macrophage-like RAW 264.7 cells
exposed to 95% O2. HMGB1 was localized primarily in the nuclei of
RAW cells that remained at RA. However, after 48 h hyperoxic
exposure (O2), HMGB1 staining was observed predominantly in
the cytoplasm of the RAW cells (Fig. 3A). This data indicates that
hyperoxia induces the active release of HMGB1 from the nuclei to
the cytoplasm of lung cells.
An important factor in regulating the translocation of HMGB1 is
its acetylation status. The lysine residues of two nuclear localiza-
tion signal (NLS) sites on HMGB1 can be acetylated. Hyperacetyla-
tion of the lysine residues on NLS1 and NLS2 induces the release of
HMGB1 from cells, whereas hypoacetylated HMGB1 tends to
remain in the nuclei [56]. To determine the acetylation status of
HMGB1 in hyperoxia, lung lysates and BALF of mice exposed to
either 3 days of hyperoxia or remained at RA were analyzed using
LC–MS/MS as previously described [2,32]. HMGB1 was primarily in
the hypoacetylated form in animals remained at RA (Fig. 3B, 21%
O2). However, HMGB1 was signiﬁcantly hyperacetylated in mice
exposed to hyperoxia (Fig. 3B, Z99% O2). Fig. 3C shows represen-
tative images of the MS/MS analysis of hypoacetylation (left) and
hyperacetylation (right) of HMGB1. These data suggest that hyper-
oxic exposure leads to hyperacetylation of HMGB1, resulting in
its pronounced translocation to the cytoplasm and subsequent
release.
Hyperoxia increases oxidative states of airway HMGB1 and induces
leukocyte inﬁltration into the lungs
Inﬂammatory ALI is deﬁned by the inﬁltration of leukocytes,
especially PMNs into the lungs [37]. To gain insights into the
mechanism underlying how HMGB1 contributes to the develop-
ment of hyperoxia-induced lung injury, we evaluated the effect of
HMGB1 on leukocyte inﬁltration in mice exposed to hyperoxia.
After 24 h of hyperoxic exposure, mice were intratracheally
instilled with 10 mg of either recombinant HMGB1 with GST-tag
or GST-tag alone [54] and exposed to Z99% O2 for an additional
24 h. Recombinant HMGB1 instillation signiﬁcantly increased the
inﬁltration of leukocytes compared to hyperoxia, control GST-tag
and RA (3473.93104/ml BALF vs. 19.7572.75104/ml BALF,
1671.8104/ml BALF, and 11.171.5104/ml BALF; Po0.01).
HMGB1 signiﬁcantly increased the inﬁltration of PMNs into the
airways, compared to either hyperoxia, GST-tag alone or RA
(2.4270.41104/ml BALF vs. 0/ml BALF and 0.3570.12104/ml
BALF, and 0/ml BALF; Po0.001) (Fig. 4A and B). In contrast, the
administration of anti-HMGB1 IgGs signiﬁcantly attenuated the
inﬁltration of leukocytes compared to those receiving vehicle or
control IgGs (39.875.8104/ml BALF vs. 87.177.1104/ml BALF
and 69.4578.7104/ml BALF; Po0.01, respectively), as well as
PMNs (0.3770.08104/ml BALF vs. 2.8670.7104/ml BALF and
2.2170.6104/ml BALF; Po0.01) in mice exposed to Z99%
O2 for an additional 24 h (Fig. 4C and D). Overall, these data
suggest that HMGB1 plays a critical role in mediating hyperoxia-
induced inﬂammatory ALI through evoking leukocyte inﬁltration
into the lungs.
Fig. 2. Pretreatment with anti-HMGB1 IgGs attenuates hyperoxia-induced inﬂammatory acute lung injury. Two hours prior to hyperoxic exposure, mice were treated
intraperitonealy with either 360 μg/mouse anti-HMGB1 IgGs (α-HMGB1) or control IgGs (CTL). The animals were then exposed to Z99% O2 for 4 days while receiving IgGs
treatment every 12 h. Total protein content in BALF (A) and wet/dry weight ratio (B) were analyzed as markers of acute inﬂammatory lung injury. Data represent means7SE
from two independent experiments, n¼9 mice per group. n, Statistically signiﬁcant compared to that of mice either treated with control antibodies or exposed to hyperoxia
alone, Po0.05.
M. Entezari et al. / Redox Biology 2 (2014) 314–322 317
Three critical cysteine residues (C23, C45 and C106) of HMGB1
are subjected to redox modiﬁcations, which affect its chemotactic
activity [52]. To determine the redox state of extracellular HMGB1
in hyperoxia exposed animals, LC–MS/MS was used to analyze
BALF of mice exposed to Z99% O2 for 3 days. MS/MS analysis
indicated that all three redox forms of HMGB1 were present in
BALF of hyperoxia exposed mice, including all reduced and
oxidized thiols, and a disulﬁde bond between C23 and C45 with
C106 reduced (Fig. 4E). However, no extracellular HMGB1 was
detected in the BALF of mice that were remained at RA (Fig. 4E).
In the lungs of both hyperoxia exposed mice and mice that
remained at RA, HMGB1 was in the reduced form (Fig. 4F). These
data suggest that hyperoxia-induced oxidative modiﬁcations of
HMGB1 occurred after its release into the airways.
Administration of anti-HMGB1 IgGs post-onset of hyperoxic exposure
attenuates hyperoxia-induced inﬂammatory acute lung injury
Although the administration of anti-HMGB1 IgGs prior to
exposing animals to hyperoxia was an important proof of concept,
strategies aimed at inhibiting HMGB1 after the onset of hyperoxic
exposure are more clinically relevant. Therefore, we assessed the
efﬁcacy of administrating anti-HMGB1 IgGs to animals post-
hyperoxic exposure on inﬂammatory ALI. As shown in Fig. 5, the
administration of anti-HMGB1 IgGs 24 h post-exposure to hyper-
oxia signiﬁcantly attenuated hyperoxia-induced inﬂammatory ALI,
as indicated by a signiﬁcant decrease in total protein content in
BALF (2.470.2103 mg/ml vs. 4.270.6103 mg/ml; Po0.01),
wet/dry weight ratio (1.0170.02 vs. 1.3670.04; Po0.05), leuko-
cyte inﬁltration (39.875.8104/ml BALF vs. 69.4578.7104/ml
BALF; Po0.01), and PMNs inﬁltration (0.3770.08104/ml BALF
vs. 2.2170.6104/ml BALF; Po0.01) (Fig. 5A). The attenuation
of inﬂammatory ALI by anti-HMGB1 IgGs was conﬁrmed by
histologic examination of lung tissue sections (Fig. 5B). Alveolar
hemorrhage and thickening of the interalveolar septum were
signiﬁcantly decreased in lung tissues of animals treated with
anti-HMGB1 IgGs compared to those treated with control IgGs or
those exposed to hyperoxia alone (Fig. 5B). These results indicate
that blocking HMGB1 after the onset of hyperoxia exposure can
alleviate hyperoxia-induced inﬂammatory ALI.
Ethyl pyruvate (EP) attenuates hyperoxia-induced inﬂammatory
acute lung injury via inhibiting HMGB1 release
Ethyl pyruvate (EP) has been reported to inhibit LPS-induced
HMGB1 secretion [44]. To investigate the effects of EP on
hyperoxia-induced lung injury, mice were given 40 mg/kg intra-
peritoneal of EP 24 h post-hyperoxic exposure. The administration
of EP signiﬁcantly decreased the inﬂammatory ALI in hyperoxic
animals as compared to animals administered vehicle control
alone, as indicated by a decreased total protein content in BALF
(1.8770.34103 mg/ml vs. 3.7170.69103 mg/ml; Po0.01)
(Fig. 6A) and wet/dry weight ratio (0.9870.02 vs. 1.370.04;
Po0.01) (Fig. 6B), and signiﬁcantly lower levels of airway
Fig. 3. Hyperoxia induces hyperacetylation and translocation of nuclear HMGB1 to the cytoplasm. C57BL/6 mice were exposed to either 4 days of Z99% O2 or remained
at RA. (A) Images of lung tissue sections (original magniﬁcation, X1000) stained with anti-HMGB1 IgGs and DAB (3, 30-diaminobenzidine) peroxidase substrate (brown color).
The red signals showed immunoﬂuoresence staining with anti-HMGB1 IgGs and Cy3 in RAW 264.7 macrophages that were either exposed to 95% O2 for 48 h or remained at
RA (original magniﬁcation, X600). (B) Representative spectra of the liquid chromatography mass spectrometric (LC–MS) characterization of peptides produced from HMGB1
derived from mice lung tissue homogenate (Lung Lysate) enzymatically cleaved with endopeptidase GluC. The presence of the peptides with molecular weights 1624 and
1133 Da indicate the hypo-acetylation of lysine residues within NLS 1 and 2, respectively. The presence of the peptides with molecular weights 1750 and 1342 Da indicate the
hyper-acetylation of lysine residues within NLS 1 and 2 respectively. (C) Representative spectra of the liquid chromatography tandem mass spectrometric (LC–MS/MS)
characterization of a peptide (amino acids 180–188) covering the lysine (K) residues within NLS 2 of HMGB1 to conﬁrm the presence or absence of acetyl modiﬁcations on
speciﬁc K residues. Acetyl modiﬁcations are represented as (ac) on speciﬁc lysine residues (K181, K182, K183 and K184) when required and b and y ions are highlighted were
appropriate.
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leukocytes (2974.9104/ml BALF vs. 70.775.8104/ml BALF;
Po0.01) (Fig. 6C) and PMNs (0.9670.3104/ml BALF vs.
370.42104/ml BALF; Po0.01) (Fig. 6D).
To determine the mechanism underlying the effects of EP on
hyperoxic ALI, levels of airway HMGB1 were determined in the
BALF of animals exposed to hyperoxia and treated with EP. As
shown in Fig. 6E, the levels of airway HMGB1 were signiﬁcantly
lower in mice treated with EP compared to those exposed to
vehicle control alone (1.7870.71 vs. 7.670.85 AU; Po0.01). The
inhibitory effect of EP on hyperoxia-induced HMGB1 release was
further conﬁrmed in RAW 264.7 cells exposed to 95% O2. EP
treatment (5 mM) signiﬁcantly reduced HMGB1 release into the
culture media of RAW cells (8.9870.06 AU vs. 11.3570.31 AU;
Po0.001) (Fig. 6F). These results demonstrate that EP protects
animals against hyperoxia-induced inﬂammatory ALI by inhibiting
HMGB1 release into the airways.
Discussion
High levels of airway HMGB1 were found in patients receiving MV,
although the contribution of HMGB1 to hyperoxia-induced ALI
remains largely undeﬁned. In the present study, we provide evidence
of HMGB1 as a critical mediator for developing ALI upon prolonged
hyperoxia exposure via recruiting PMNs. Our results manifest that
increased levels of airway HMGB1 during hyperoxia are linked to the
induction of inﬂammatory ALI, while inhibition of HMGB1 protects
lung tissue against hyperoxia-induced injury through decreasing
pulmonary neutrophil accumulation. Our data also show that EP has
protective effects against hyperoxia-induced inﬂammatory ALI by
inhibiting hyperoxia-induced HMGB1 release into the airways.
Hyperoxia-induced leukocyte inﬁltration plays a critical role in the
development of ALI [4]. Several lines of evidence presented in this
report demonstrate that elevated levels of airway HMGB1 mediate
leukocyte inﬁltration under hyperoxic conditions. First, levels of airway
HMGB1 increased time-dependently upon hyperoxic exposure for up
to 4 days (Fig. 1A). The elevated levels of airway HMGB1 were
preceding the recruitment of neutrophils into the airways and lung
injury (Fig. 1C and B). In addition, instillation of 10 μg of HMGB1,
amount that is similar to those found in patients with ALI [40],
signiﬁcantly increased leukocyte inﬁltration into the airways of mice
exposed to hyperoxia (Fig. 4A and B). Furthermore, pretreatment of
mice exposed to hyperoxia with neutralizing anti-HMGB1 antibodies
ameliorated hyperoxia-induced neutrophil inﬁltration and lung injury
Fig. 4. Hyperoxia increases oxidative states of airway HMGB1 that induces leukocyte inﬁltration into the lungs. C57BL/6 mice were given 10 μg rHMGB1- or
gluthatione-s-transferase (GST-tag) as control (CTL) via intratracheal instillation 24 h post-hyperoxic (Z99% O2) exposure. Mice were then exposed to hyperoxia for an
additional 24 h. Total numbers of leukocytes and PMNs inﬁltrated into the airways were analyzed as markers of inﬂammatory ALI. Data represent means7SE from two
independent experiments, n¼9 mice per group. n, Statistically signiﬁcant vs. the values of the control group which received GST-tag, Po0.05 (A and B). Mice were treated
intraperitonealy with either 360 μg/mouse anti-HMGB1 IgGs (α-HMGB1) or control IgGs (CTL) 2 h prior to hyperoxic exposure. Mice were then exposed to Z99% O2 and
received either α-HMGB1 IgGs or control IgGs intraperitonealy every 12 h for 4 days while still being exposed to Z99% O2. Total numbers of leukocytes and PMNs inﬁltrated
into the airways were analyzed. Data represent means7SE from two independent experiments, n¼9 mice per group. n, Statistically signiﬁcant vs. mice treated with control
IgGs, Po0.05 (C and D). BALF and lung tissue from mice exposed to Z99% O2 for 3 days or that remained at RA, were analyzed for the presence of three redox forms of
HMGB1: disulﬁde, all thiol and sulfonic acid using LC–MS (E and F).
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(Figs. 2 and 4C and D). Thus, our results are similar to those of other
studies indicating that HMGB1 is a critical mediator of ALI in various
pathologic conditions [1,23,26,27]. The inactivation of HMGB1 with
speciﬁc antibodies improved survival of animals with severe poly-
microbial sepsis, reduced high tidal volume ventilation-induced lung
injury, and diminished endotoxin and hemorrhage-induced increases
in pulmonary level of inﬂammatory cytokines [1,27,33,43,49].
Together, these studies indicate that HMGB1 plays an important role
in neutrophil-mediated lung injury induced by either oxidative stress
or reagents.
In this report, we demonstrated that hyperacetylation of HMGB1
may be a critical mechanism underlying hyperoxia-induced HMGB1
release from lung cells. Fig. 3 shows that hyperoxia-induced HMGB1
hyperacetylation corresponds to the cytoplasmic translocation and
release of nuclear HMGB1. Mass spectrometric analysis of lung
lysates shows that four lysine residues on NLS1 and ﬁve on NLS2
motifs of HMGB1 were hyperacetylated after 3 days of exposure to
hyperoxia, while no hyperacetylation of HMGB1 was observed in
lung lysates of mice remained at RA (Fig. 3B and C). These results
suggest a correlation between hyperoxia-induced HMGB1 transloca-
tion and subsequent release with hyperacetylation of lysine residues.
Under normoxic conditions, acetylation of lysine residues of HMGB1
has also been implicated to regulate this nucleocytoplsamic shuttling
and its subsequent active release from LPS-activated monocytes and
macrophages [8]. These results suggest the involvement of hyper-
acetylation in hyperoxia-induced HMGB1 release, although further
studies are needed to establish a causal relation between hyperace-
tylation of HMGB1 and its release under hyperoxic conditions.
Post-translational redox modiﬁcations of three critical thiol
groups of HMGB1 are important in determining its bioactivity
[41]. Although no detectable extracellular HMGB1 was found in
the airways of mice exposed to RA, airway HMGB1 molecules in
mice exposed to prolonged hyperoxia were found in different redox
states, including all reduced thiol groups and disulﬁde forms
(Fig. 4E and F). Two forms of HMGB1, all reduced and disulﬁde
(C23 and C45), possess chemoattractant and cytokine-inducing
activities, respectively, while terminally oxidized forms lack any
inﬂammatory activity [25,41,48,53]. The presence of the two not-
terminally oxidized forms of HMGB1 in the airways of hyperoxia-
exposed mice supports HMGB1's role in hyperoxia-induced inﬂam-
matory responses. Further quantiﬁcation of each redox form of
HMGB1 in hyperoxic airways and characterization of their speciﬁc
roles in the inﬂammatory response still remain to be determined.
Interestingly, airway HMGB1 molecules present in mice exposed to
hyperoxia exist only in its hyperacetylated form, even though they
are in different redox states (Figs. 4 and 5). Currently, however, it is
not clear and needs to be clariﬁed whether hyperacetylation of the
different redox forms of HMGB1 affect its inﬂammatory activities.
Pretreatment with antibodies provides proof of the concept that
airway HMGB1 mediates hyperoxia-induced ALI. However, adminis-
tration of reagents to inhibit the accumulation or the activity of airway
HMGB1 post-onset of hyperoxic exposure would be more clinically
relevant. Our results shown in Figs. 5 and 6 demonstrate that this
strategy is effective in ameliorating hyperoxia-induced both number of
neutrophils in the lungs and ALI. Though highly effective, high
production costs and large molecular sizes, which affect pharmacoki-
netics, may limit clinical use of antibody therapies [11]. Thus, the use
of EP, a small molecule, in reducing hyperoxia-induced inﬂammatory
ALI (Fig. 6), may circumvent the limitations associated with antibody
therapies. The amelioration of lung injury by EP was most likely due to
a decrease in hyperoxia-induced accumulation of airway HMGB1
(Fig. 6). Others have shown that EP treatment also decreased LPS-
induced HMGB1 release, even with delayed treatment, 2 h after LPS
administration and 24 h after cecal ligation and puncture surgery
[36,46,54]. Similarly, EP attenuated high tidal volume induced HMGB1
expression and ameliorated lung injury [22].
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CTL /O2
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Fig. 5. Administration of anti-HMGB1 IgGs post-onset of hyperoxic exposure attenuates hyperoxia-induced inﬂammatory acute lung injury. After 24 h of exposure to
Z99% O2 mice were treated intraperitonealy with 360 μg/mouse of either anti-HMGB1 IgGs (α-HMGB1) or control IgGs (CTL) every 12 h for 3 days while still being exposed
to Z99% O2. Total protein content, wet/dry weight ratio, and total numbers of leukocytes and PMNs inﬁltrated in airways were analyzed as markers of inﬂammatory ALI.
Data represent means7SE from two independent experiments, n¼13 mice per group. n, Statistically signiﬁcant vs. mice treated with control IgGs, Po0.05
(A). Hematoxylin–eosin-stain of the lung tissues from control and experimental groups of mice (original magniﬁcation 200 ). Images are representative lung sections
from 5 mice per group. Asterisks (n) show the alveolar hemorrhage and arrows show the thickening of the interalveolar septum in lung tissues of animals (B).
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In conclusion, this study provides a novel mechanism under-
lying hyperoxia-induced inﬂammatory ALI and potential thera-
peutic approaches to mitigate such injury. We ﬁnd that HMGB1
mediates, at least in part, hyperoxia-induced neutrophil inﬁltra-
tion into the lungs. Post-translational modiﬁcations of HMGB1
such as hyperacetylation may play a critical role in translocation of
nuclear HMGB1 to the cytoplasm and subsequent release into the
airways. Inhibition of extracellular HMGB1 and/or its accumula-
tion in the airways, with either antibodies or small molecules,
provides signiﬁcant protection against hyperoxic lung injury. Thus,
therapeutic approaches targeting airway HMGB1, using small
inhibitory molecules, such as EP, may attenuate lung injury in
patients on oxygen therapy.
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